OptiNose

OptiNose — Q2 2024 Earnings Presentation

16 slides from OptiNose's earnings presentation, Aug 8, 2024

  1. Slide 1: Building a Leading ENT / Allergy Specialty Company

    Building a Leading ENT / Allergy Specialty Company Corporate Presentation August 8, 2024

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this

  3. Slide 3: Today's Agenda

    3 Today’s Agenda Introduction and Key Takeaways Ramy Mahmoud, MD, MPH CS Launch Update Paul Spence Q2 2024 Performance and FY 2024 Financial Guidance Jonathan Neely Closing Remarks Ramy Mahmoud, MD, MPH

  4. Slide 4: Key Takeaways

    4 Key Takeaways • New indication creates a significant near- term growth opportunity with up to a 10x multiple on the TAM based on patients who are currently treated by a physician • Current sales footprint of 75 territories and phased modest incremental commercial investment, expected to be suffici

  5. Slide 5: CS Launch Updates

    epee CS Launch Updates

  6. Slide 6: Commercial Update

    6 Commercial Update • Core tactics: Sales Force, Non-Personal Promotion, Congresses, Peer-to-peer education • Delivered ~35,000 Calls in Q2; 60% of calls to XHANCE-naïve and low-frequency prescribers • Early indications that efficacy-focused discussions, at sufficient frequency, can lead to product

  7. Slide 7: Addition of XHANCE to National Commercial Formularies

    7 Addition of XHANCE to National Commercial Formularies As announced at the end of June, XHANCE was added to Express Scripts’ national formularies including the National Preferred, Flex, and Basic formularies These formularies are among the largest commercial formularies in the U.S. with more than 2

  8. Slide 8: Q2 2024 Performance

    epee Q2 2024 Performance

  9. Slide 9: Financial Review – Second Quarter 2024

    9 Financial Review – Second Quarter 2024 Average net revenue per prescription increased 44% YoY in context of our focus on growing profitable prescriptions XHANCE Net Revenues of $20.5 million increased 5% compared to Q2 2023 As expected, Operating Expenses increased ~$4M $21.1 $25.1 Q2 '23 Q2 '24 (

  10. Slide 10: Financial Review – YTD June 2024

    10 Financial Review – YTD June 2024 Average net revenue per prescription increased 51% YoY in context of our focus on growing profitable prescriptions XHANCE Net Revenues of $35.4 million increased 13% compared to YTD June 2023 As expected, Operating Expenses increased ~$1M $45.6 $46.8 YTD June '23

  11. Slide 11: 2024 Outlook

    epee 2024 Outlook

  12. Slide 12: Full Year 2024 Financial Guidance

    12 Full Year 2024 Financial Guidance GAAP Operating Expenses (SG&A and R&D Expenses) Expected to be between $95 to $101 million; approximately $6 million of which represents stock-based compensation XHANCE Net Revenue FY 2024 expected to be between $85 to $90 million, an increase of 20% to 27% compa

  13. Slide 13: Closing Remarks

    Closing Remarks

  14. Slide 14: Key Takeaways

    14 Key Takeaways • New indication creates a significant near- term growth opportunity with up to a 10x multiple on the TAM based on patients who are currently treated by a physician • Current sales footprint of 75 territories and phased modest incremental commercial investment, expected to be suffic

  15. Slide 15: Investor Relations – Optinose

    15 Investor Relations – NASDAQ: OPTN Optinose Investor ContactAnalyst Coverage 1 Jefferies: Glen Santangelo Lake Street: Thomas Flaten Piper Sandler: David Amsellem H. C. Wainwright: Matthew Caufield 1 - Optinose is followed by the analysts listed above. Please note that any opinions, estimates or f

  16. Slide 16: Building a Leading ENT / Allergy Specialty Company

    Building a Leading ENT / Allergy Specialty Company Corporate Presentation August 8, 2024

Optinose — Q2 2024 Earnings Presentation on 6ix